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Introduction: Drug-drug interactions constitute a predictable and 
in many cases avoidable cause of adverse drug reactions and thera-
peutic failure. We conducted a register-based study to investigate the 
prevalence of prescribed combinations of interacting drugs in the 
whole Swedish population (Holm et al. Eur J Clin Pharmacol. 2014).
Material and Methods: A retrospective, cross-sectional register 
study was conducted, covering four months in 2010. Data from 
the Prescribed Drug Register on all dispensed drug prescriptions in 
Swedish pharmacies from January 1 to April 30 were linked to the 
drug-drug interaction database SFINX. The analysis focused on drug 
interactions classified in the database as clinically relevant that can be 
handled, e.g. by dose adjustments (C-interactions), and clinically rele-
vant interactions that should be avoided (D-interactions). Interactions 
were categorized according to clinical consequence and drug type and 
prevalences of interacting drug combinations were described. The 
study was approved by the Regional Ethics Committee.
Results: About half of the population were dispensed at least one 
drug prescription. Mean (SD) number of dispensed drugs was 3.8 
(3.4). About 2.5 million potentially interacting drug combinations 
were identified in the study population of 9.3 million people. Among 
detected interactions 38% were classified as C-interactions and 3.8% 
as D-interactions. About half of all C- and D-interactions were com-
binations of drugs with potential to cause therapeutic failure. The 15 
most prevalent combinations accounted for 80% of D-interactions. 
The 10 most prevalent individual drugs were involved in 94% of all 
D-interactions.
Conclusions: A limited number of drugs and a few specific drug 
combinations account for the majority of D-interactions, i.e. clini-
cally relevant interactions that should be avoided, in Sweden. About 
half of interacting drug combinations among C- and D-interactions 
potentially leads to treatment failure.
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Uracil catabolism is crucial for the pharmacokinetics of the chemo-
therapeutic 5-fluorouracil (5-FU) since 5-FU is degraded by the 
same pathway. Decreased activity of the first catabolizing enzyme, 
dihydropyrimidine dehydrogenase (DPD), is a major predictor of 
5-FU toxicity with known risk variants in the DPD gene (DPYD) 
accounting for ~30% of toxicities. However, not all toxicity cases 
can be explained by DPYD risk variants. To date, the phenotypic 
variability in the catabolism downstream of DPD by dihydro-
pyrimidinase (DHP) and β -ureidopropionase (bUP), potentially 
contributing to 5-FU toxicity, has not been investigated. Thus, we 
aimed to characterize the baseline phenotypic variability of endog-
enous metabolites and metabolic ratios of 5-FU catabolism enzymes 
and to correlate the phenotype with genetic variation in the DHP 
and bUP genes (DPYS and UPB1).
Material and Methods: Three variants in DPYS and UPB1 previ-
ously associated with 5-FU toxicity were genotyped in 320 healthy 
volunteers and their plasma uracil, dihydrouracil (UH2), β -ureidopro-
pionic acid (UPA), and β -alanine (BAL) concentrations were deter-
mined by LC-MS/MS.
Results and Conclusions: High inter-individual variability in all met-
abolic ratios was observed. Sex-dependent differences were detected 
at each enzymatic step in the uracil catabolism pathway, with lower 
metabolite levels (P ≤ 0.007) in women. Moreover, lower UPA/UH2 
ratios (P < 0.001) were observed in women, suggesting that reduced 
5-Fluoro-UH2 catabolism may contribute to higher fluoropyrimi-
dine toxicity rates observed in females. Furthermore, volunteers 
carrying DPYS variant c.265-58T> C had lower UH2 plasma levels 
(P = 0.033) and higher UPA/UH2 ratios (P = 0.036) and carriers 
of the UPB1 variant c.1-80C> G showed lower BAL plasma levels 
(P = 0.004). These initial results are in agreement with the previously 
observed reduced fluoropyrimidine toxicity in c.265-58C carriers 
and increased toxicity in carriers of c.1-80G, indicating a possible 
functional effect related to these variants.
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Introduction: The growing aging of population and increasing preva-
lence of chronic diseases require the simultaneous use of drugs, lead 
to the issue of polypharmacy and potentially interactions and inap-
propriate use.
Aim: To characterize polymedicated elderly and related factors, iden-
tify potentially interactions and inappropriate medication in elderly.
Material and Methods: This cross-sectional study was based on 
a questionnaire applied to 69 elderly (≥ 65 years) from northern 
Portugal. It was considered as polymedicated seniors taking ≥ 5 
drugs. Beers list and the Delafuente classification were used to evalu-
ate the therapeutic and possible interactions. It was used descriptive 
statistics and a model of binary regression, with a significance of 5%. 
The study was approved by Ethics Committee.
Results: The sample consisted mainly of males (53.6% vs. 46.4%), 
aged between 66 and 99 years (mean 82.01), while 65.2% have 
more than 80 years. However, most elderly are not polymedicated 
(58%), on average 4.61 different drugs are administered per day 
(maximum= 19), antihypertensives (36.2%) and antacids (30.04%) 
are the most prescribed. Hypertension and depression increase the 
risk of polymedication eightfold (P = 0.004) and fivefold (P = 0.011) 
respectively. Female gender seems increase the risk of polypharmacy 
threefold, although not statistically significant (P = 0.102), and 
regarding age, the older age group (> 85 years) seems reduces the 
risk of polypharmacy in 0.6 fold, but also not statistically significant. 
According with Delafuente classification, 1.4% of elderly has poten-
tially drug interactions (Omeprazole and Iron salts). According to 
the list of Beers, 5.8% of seniors take drugs that classified as having 
some indications (hydroxyzine, amitriptyline).
Conclusions: Regarding polypharmacy, 42% of elderly are poly-
medicated with an average of about 5 different drugs per day, anti-
hypertensives and antacids the most prescribed. Hypertension and 
depression are highly associated with polypharmacy. We identified 
poster presentations
August 2015 e101
one potentially drug interaction and about 6% of elderly taking drugs 
that classified as having some indications.
Key words: Beers list, Delafuente classification, Elderly, Inappropriate 
medication in elderly, Medication interactions, Polypharmacy.
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Background: The use of dried blood spots (DBS) has gained in popu-
larity in the last few years over conventional whole blood or plasma 
sampling for PK or drug monitoring. In order to overcome the impact 
that haematocrit has on the spreading of the applied drop of blood, 
precise knowledge of the collected volume is crucial for the determi-
nation of drug/metabolites concentrations.
Material and Methods: Although the collection of an accurate capil-
lary volume using a volumetric micropipette is simpler than venous 
blood collection, it still needs to be conducted by trained technicians 
using dedicated instruments. To simplify this process a new capillary 
blood collection device has been developed. The prototype integrates a 
patented microfluidic plate (WO/2013/144743) allowing for accurate 
volume control and a conventional filter paper card for blood storage.
The concentrations and pharmacokinetic profiles of a 
P-glycoprotein (P-gp) and six cytochrome P450 (CYP) probes and 
their metabolites obtained with the new sampling device have been 
compared with a conventional volumetric micropipetting method in 
a clinical trial including 30 volunteers who have received the Geneva 
cocktail for CYP and P-gp phenotyping. The quantification was done 
using a previously validated LC/MS-MS method.
Results: Concentrations obtained with the new microfluidic sam-
pling device showed excellent correlation with conventional micro-
pipetting concentrations with slopes values close to 1 (0.91 – 1.03) 
and determination coefficients R2> 0.90 for all of the 13 analysed 
substances. Sampling could be successfully performed by the volun-
teers themselves with almost no previous training.
Conclusion: DBS technique combined with an innovative sampling 
device and a sensitive analytical method can be used as a self-test for 
CYP and P-gp phenotyping The use of this technique can be further 
enlarged to the quantification of other substances for PK studies and 
therapeutic drug monitoring.
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Background: Therapeutic drug monitoring (TDM) can help cli-
nicians to optimize dosing of medicines. Evidence on the use of 
this service in psychiatry mainly refers to questionnaire studies. 
The aim of this study was to use register data to describe the 
prevalence of TDM for antidepressants and antipsychotics dur-
ing 2006-2013.
Material and Methods: The study population consisted of indi-
viduals, ≥ 5 years of age, residing in the Stockholm County. The 
prevalence of TDM for each study year was calculated with the 
number of individuals in whom TDM had been performed as nomi-
nator (extracted from the TDM database at Karolinska University 
Laboratory) and the number of treated individuals as denominator 
(extracted from the Swedish Prescribed Drug Register). The preva-
lence of TDM was compared between substances according to the 
level of TDM recommendation by guidelines.
Results: In 2006, 641 in 133,275 (0.48%) individuals on antide-
pressants were subjected to TDM. In 2013, the corresponding figure 
was 580 in 162,998 (0.36%). In 2013, the most frequently analysed 
antidepressants were nortriptyline (6.2%) and clomipramine (4.5%). 
For patients on antipsychotics, the prevalence of TDM increased 
between 2006 and 2013, from 729 in 31,463 (2.3%) to 1,338 in 
32,534 (4.1%). In 2013, the most frequently analyzed antipsychotics 
were clozapine (29%) and perphenazine (22%). For both antidepres-
sants and antipsychotics, TDM was more common in men than in 
women. A trend to a greater prevalence was found for substances 
strongly recommended for TDM than for substances with a lower 
level of recommendation (5.6% vs. 1.1%; P = 0.063).
Conclusions: Each year, less than one in 200 patients on antide-
pressants and less than one in 20 patients on antipsychotics have 
their treatment personalized by means of TDM. The use of TDM is 
increasing for antipsychotics but not for antidepressants. Men are 
more frequently monitored by plasma concentrations than women.
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Background: Elderly patients are highly susceptible to poly-pharmacy, 
which may cause drug–drug interactions and relevant hospitalisations. 
These often involve NSAIDs (Non- Steroidal-Anti-Inflammatory-
Drugs), which are inappropriately prescribed. This study aimed to 
investigate the risk of kidney injury and bleeding following various 
NSAIDs interactions in the elderly poly-treated population.
Material and Methods: An historic cohort study based on adminis-
trative databases of the Local Health Authority of Bologna (866,000 
inhabitants) was performed. Patients with at least a NSAID prescrip-
tion in the first semester of 2012 were selected among elderly (≥ 65 
years) poly-treated (> 4 different drugs) subjects. Co-prescriptions 
of NSAIDs + ACE- Inhibitors (or sartans), NSAIDs + diuretics, 
NSAIDs + ACE-Inhibitors (or sartans) + diuretics (triple whammy), 
NSAIDs + metformin, NSAIDs + SSRIs, NSAIDs + corticosteroids 
and NSAIDs + warfarin were considered as potential interactions. 
Kidney injury and bleeding hospitalisations represented the outcome 
measures. Kaplan-Meier curves and Cox regression model were used 
to estimate the risk of two outcomes following interactions. Hazard 
Ratios (HRs), with 95% Confidence Interval (95CI), were adjusted 
for gender, age and concomitant drugs.
Results: Out of 34,353 elderly poly-treated patients, 7,420 subjects 
received NSAIDs (60.8% female, 76.9 average age). Among these, 
85.7% was exposed to NSAIDs + ACE-Inhibitors(or sartans), 69.9% 
to NSAIDs + diuretics, 32.8% to triple whammy, 21.6% to NSAIDs + 
metformin, 20.1% to NSAIDs + SSRIs, 17.1% to NSAIDs + cor-
ticosteroids and 8.2% to NSAIDs + warfarin. A significant risk of 
kidney injury was found only for triple whammy (adjHR: 1.33; 95CI: 
